Merigolix (TU2670)
Phase 2Endometriosis candidate that met statistical significance on its primary endpoint, reduction in menstrual pain, in a Phase 2a trial in five European countries.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has Phase 2 data for its endometriosis and immuno-oncology candidates and is in licensing talks.
Roles often seen at this stageClinical & PV · BD & licensing · Research & development
Develops drug candidates for endometriosis, immuno-oncology and hemophilia, and also runs a drug process development and protein analysis services business (CDAO).
Endometriosis candidate that met statistical significance on its primary endpoint, reduction in menstrual pain, in a Phase 2a trial in five European countries.
Immuno-oncology candidate combined with Keytruda; at ASCO 2026 it reported responses in 9 of 12 first-line head and neck cancer patients.
Recombinant hemophilia bypassing-agent candidate with extended half-life, in a Phase 1b trial in Europe.
Released interim Phase 2 results of tosporsertib with Keytruda in head and neck cancer in an ASCO 2026 abstract.
Reported record consolidated revenue of 12.3 billion won for 2025.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.